The issue was discussed at a public consultation organized by the Medicines and Medical Devices Agency in conjunction with the Department of Health.
The system envisages centralized collection of data on actual drug balances at manufacturers, distributors and in the pharmacy network. Based on this information, the regulator will be able to promptly identify imbalances, forecast possible disruptions and make management decisions to ensure uninterrupted supplies.
The Agency notes that the lack of a unified stock accounting mechanism currently limits the government’s ability to respond to shortages, especially for socially important and vital drugs.
In parallel, an information system for traceability of medicines is being developed. It is aimed at verifying the authenticity of products and preventing falsified medicines from entering the legal supply chain in accordance with the European Union’s requirements for the safety of medicines.
Stock monitoring and traceability systems for medicines are expected to promote compatibility with relevant European mechanisms and generally harmonize the national regulatory framework with EU norms. Their development is part of the modernization and digitalization of the pharmaceutical sector.
It should be noted that currently there is no centralized accounting of drug stocks, deficits are recorded based on requests from patients and pharmacists. The system will make it possible to collect data from all market participants on a daily basis, to monitor stocks in real time. In 2026, it is planned to approve the legislative framework, followed by the development of the terms of reference, market analysis and implementation of the pilot phase, including the procurement of services for the development, testing and implementation of the system.
The budget of the project is 10.3 million lei. The project is realized with the financial support of the European Union.
